[Tree] AstraZeneca's investment in US R&D and manufacturing

Version 0.25 (2024-11-16 04:54:54.345000)

updates: Updated investment details and job creation plans

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.24 (2024-11-13 13:35:51.764000)

updates: AstraZeneca increases U.S. investment to $3.5 billion

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.23 (2024-11-12 12:47:09.214000)

updates: AstraZeneca invests $3.5 billion in US operations

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.22 (2024-06-18 18:59:40.726000)

updates: Pfizer sued in Kansas over COVID-19 vaccine

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.21 (2024-05-08 13:58:37.831000)

updates: AstraZeneca to withdraw Covid vaccine

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.2 (2024-04-04 23:22:43.499000)

updates: AstraZeneca acquires Fusion Pharmaceuticals; AstraZeneca caps inhaler costs; Fusion Pharmaceuticals downgraded by Morgan Stanley; Boehringer to lay off salespeople as Humira biosimilar sales lag

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.2 (2024-04-04 23:22:43.499000)

updates: AstraZeneca acquires Fusion Pharmaceuticals; AstraZeneca caps inhaler costs; Fusion Pharmaceuticals downgraded by Morgan Stanley; Boehringer to lay off salespeople as Humira biosimilar sales lag

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.19 (2024-03-19 21:25:22.884000)

updates: Lawsuit against AstraZeneca by Puma Biotech over patent infringement

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.18 (2024-03-19 20:25:14.568000)

updates: Morgan Stanley downgrades Fusion Pharma rating, raises target to $21

  • ➔
  • ➔
  • ➔
Version 0.17 (2024-03-19 16:03:11.817000)

updates: AstraZeneca acquires Fusion Pharmaceuticals

  • ➔
  • ➔
Version 0.16 (2024-03-18 20:19:59.336000)

updates: AstraZeneca announces a price cap for inhalers to help vulnerable patients

  • ➔
Version 0.15 (2024-03-04 20:35:09.124000)

updates: Updates on patent cases involving Johnson & Johnson and Takeda

  • ➔
Version 0.14 (2024-03-02 03:23:09.480000)

updates: Johnson & Johnson wins patent case in Delaware

  • ➔
Version 0.13 (2024-03-01 22:33:35.159000)

updates: Catalyst Pharmaceuticals reports strong 2023 growth

  • ➔
Version 0.12 (2024-02-28 18:35:16.257000)

updates: Inclusion of Syndax Pharmaceuticals' progress in drug development

  • ➔
Version 0.11 (2024-02-23 08:22:26.649000)

updates: Inclusion of Rigel Pharmaceuticals' acquisition of GAVRETO for cancer treatment

  • ➔
Version 0.1 (2024-02-16 03:17:49.437000)

updates: Addition of information about Petros Pharmaceuticals entering into a licensing agreement for AI software in ED treatment

  • ➔
Version 0.09 (2024-02-15 02:11:58.081000)

updates: Add information about Clarity Pharmaceuticals' breakthrough in prostate cancer imaging

  • ➔
Version 0.08 (2024-02-13 06:32:15.136000)

updates: Integration of Basilea's financial results and portfolio expansion in 2023

  • ➔
  • ➔
Version 0.07 (2024-02-08 10:58:35.709000)

updates: AstraZeneca expects revenue and profit growth in 2024

  • ➔
Version 0.06 (2024-01-18 10:48:01.530000)

updates: Added information about three biotech stocks to watch for groundbreaking advances

  • ➔
Version 0.05 (2024-01-12 18:04:07.224000)

updates: Includes additional information on the biotech industry and recommendations for other biotech stocks

  • ➔
  • ➔
  • ➔
Version 0.04 (2023-12-26 11:02:20.743000)

updates: Integration of Wall Street analysts' recommendations for growth stocks

  • ➔
  • ➔
Version 0.03 (2023-12-01 05:50:12.250000)

updates: Updated information on recommended biotech stocks

  • ➔
Version 0.02 (2023-11-30 10:44:59.626000)

updates: Added information about JPMorgan's stock recommendations

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.01 (2023-11-27 15:38:29.929000)

updates: Integration of information about stocks with upside potential

  • ➔
  • ➔
  • ➔
Version 0.0 (2023-11-14 16:18:37.309000)

updates:

  • ➔
  • ➔